Investigational Immunotherapy Trials for Bladder Cancer

The Keynote bladder cancer clinical trials are studying an investigational drug, pembrolizumab, to see if it is safe and if it helps slow down or stop the growth of bladder cancer. The most common type of bladder cancer is urothelial carcinoma. This type of cancer begins when cells insider the urinary bladder start to grow rapidly. As more cancer cells build up they form a tumor, which can grow through the layers of the bladder and spread to other areas of the body. When the cancer has not grown into the muscle layer of the bladder it is called non-muscle invasive bladder cancer. 

Pembrolizumab is an investigational immunotherapy that may help the body’s immune system attack cancer cells. When a cancer cell binds to an immune cell, the immune cell can’t do its job. These trials want to see if pembrolizumab can block cancer cells from binding with immune cells to help allow the immune cells to work properly.

Participating in a clinical trial is an important decision. Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your doctor first.

You can also call our clinical trial information center at 1-888-577-8839 to learn more.

Clinical Trials: Important Information to Consider

There is a lot to consider when deciding whether to participate in a clinical study. Any clinical study includes risks, which the study doctor will review with you. Make sure you understand the risks before participating.